TTrialPathMatch Me to Trials
← Back to trials
RecruitingHematologic MalignancyAMLALL

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Eligible age

1–21 yrs

Accepts

All genders

Locations

21 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

You may qualify if…

  • ✓ Age
  • ✓ Patients must be ≥ 1 and ≤21 years of age at the time of study enrollment.
  • ✓ Diagnosis
  • ✓ Relapsed and/or refractory hematologic malignancy (including, but not limited to, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, mixed phenotype acute leukemia, acute undifferentiated leukemia, blastic plasmacytoid dendritic cell neoplasm, Hodgkin lymphoma, and non-Hodgkin lymphoma).
  • ✓ Tumor cells must demonstrate surface expression of CD123 at the time of enrollment by flow cytometry or immunohistochemistry, as defined by the local institution.
  • ✓ Disease Status:
  • ✓ Monotherapy, Part 1
  • ✓ Second or greater relapse; or

You may not qualify if…

  • ✕ Disease Status:
  • ✕ Patients with CNS disease are not eligible for Part 1.
  • ✕ Patients with isolated CNS disease are not eligible for Part 1 or Part 2.
  • ✕ Patients with isolated non-CNS disease are eligible for Part 1 and Part 2.
  • ✕ Concomitant Medications
  • ✕ Corticosteroids - Patients receiving corticosteroids for disease control who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible.
  • ✕ Investigational Drugs - Patients who are currently receiving another investigational drug are not eligible. The definition of "investigational" for use in this protocol means any drug that is not licensed by the FDA, Health Canada or the Therapeutic Goods Administration to be sold in the countries they govern. (United States, Canada and Australia)
  • ✕ Anti-cancer Agents - Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible \[with the exceptions being laid out in the inclusion criteria under 'Prior Therapy'\]. Intrathecal chemotherapy (at the discretion of the primary oncologist) may be given up to one week prior to the initiation of study treatment (day 1 therapy).

Where it's recruiting

California

Los Angeles · Orange · San Francisco

Colorado

Denver

District of Columbia

Washington D.C.

Florida

Miami

Georgia

Atlanta

Illinois

Chicago

Indiana

Indianapolis

Maryland

Baltimore · Bethesda

Michigan

Ann Arbor

Minnesota

Minneapolis

New York

New York

Source: ClinicalTrials.gov · NCT05476770 · last updated 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Ex · TrialPath